Preventive Medicine, Public Health & General Preventive Medicine · Rockport, TX
NPI
1447241955
Since 2005
Specialty
Preventive Medicine, Public Health & General Preventive Medicine
Code 2083P0901X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
2600 Lakeview Dr, Suite D
Rockport, TX, 78382
Phone (361) 790-5155
Groups this clinician bills Medicare through
Medicare paid, 2024
$52K
664 services
Medicare patients, 2024
131
Average age 74
Drug cost, 2024
$6.1M
5,423 prescriptions
Company payments, 2025
$181K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher P Lucci was code 99214 (office e&m - established), 345 times for 114 patients. In total Christopher P Lucci billed 664 services in 21 codes, and Medicare paid $52K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-04-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 345 | 114 | $84.03 | $29K |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 73 | 73 | $123.46 | $9,013 |
| 99213 Office E&M - Established | Office | 63 | 46 | $47.89 | $3,017 |
| 95251 Test - Miscellaneous | Office | 58 | 17 | $23.20 | $1,346 |
| 99212 Office E&M - Established | Office | 21 | 15 | $25.15 | $528 |
| 96372 Injection Administration | Office | 21 | 12 | $9.78 | $205 |
| 99487 Chronic, Principal, and Transitional Care Management | Office | 19 | 11 | $80.81 | $1,535 |
By year: 2022 $44K for 534 services; 2023 $54K for 645 services; 2024 $52K for 664 services.
Medicare prescription drug claims, 2024
In 2024, the drug Christopher P Lucci prescribed most often to Medicare patients was Ozempic (Semaglutide), with 408 prescriptions and refills. In total Christopher P Lucci wrote 5,423 Medicare prescriptions that cost $6.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 408 | 458 | 56 | $423K |
| Rosuvastatin Calcium Generic | 309 | 833 | 81 | $4,422 |
| Celecoxib Generic | 164 | 224 | 34 | $4,536 |
| Atorvastatin Calcium Generic | 158 | 408 | 42 | $1,659 |
| Levothyroxine Sodium Generic | 157 | 374 | 40 | $1,375 |
| Synthroid Levothyroxine Sodium | 136 | 291 | 28 | $13K |
| Mounjaro Tirzepatide | 136 | 137 | 16 | $138K |
| Zolpidem Tartrate Generic | 131 | 166 | 24 | $907 |
| Lisinopril Generic | 128 | 314 | 31 | $728 |
| Kerendia Finerenone | 116 | 134 | 15 | $83K |
| Xarelto Rivaroxaban | 108 | 152 | 19 | $82K |
| Farxiga Dapagliflozin Propanediol | 102 | 154 | 20 | $82K |
| Tramadol Hcl Generic | 88 | 98 | 28 | $1,061 |
| Amlodipine Besylate Generic | 81 | 166 | 18 | $440 |
| Korlym Mifepristone | 80 | 80 | Under 11 | $3.8M |
Brand drugs: 2,044 claims; generic drugs: 3,334 claims; opioid claims: 101.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher P Lucci $181K ($181K in general payments such as food, travel and fees) from 15 companies. The largest payer was Corcept Therapeutics with $104K.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 85 | $104K |
| Novo Nordisk Inc NVO | 66 | $77K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 8 | $199 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $97.82 |
| Mannkind Corporation MNKD | 3 | $85.15 |
| Xeris Pharmaceuticals, Inc. | 4 | $85 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $84.22 |
| Recordati_rare_diseases_inc. | 2 | $64.76 |
| Tactile Systems Technology Inc TCMD | 1 | $31.27 |
| Beta Bionics, Inc. BBNX | 2 | $27.42 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.